Anticancer Candidate Strengthens Bones and Prevents Weight Gain in Postmenopausal Mice
A preclinical study in post-menopausal bone loss mouse models found that CADD522, a small-molecule drug targeting RUNX2, protected against osteoporosis, prevented fat gain, and reversed some of the metabolic changes linked to menopause. The post Anticancer Candidate Strengthens Bones and Prevents Weight Gain in Postmenopausal Mice appeared first on GEN - Genetic Engineering and Biotechnology News…
A newly developed anticancer drug, CADD522, has shown promise in preventing osteoporosis and reducing weight gain in postmenopausal mice, according to research led by scientists at the University of East Anglia. The small molecule inhibitor of the RUNX2 transcription factor was found to protect against bone loss and improve lipid metabolism in the mice.
While currently in development for cancer therapy, CADD522 may also have potential as a new treatment for osteoporosis, which affects one in three women over the age of 50. The drug's unique ability to address both bone health and metabolic changes linked to menopause could lead to a new generation of osteoporosis treatments with fewer side effects and broader applicability.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
